RxDoctor Payments Data

Melissa Shinder, DPM

Primary Podiatric Medicine · Mount Laurel, NJNPI 1356606347

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Smith+Nephew at 32.6% of the total. Reporting peaked in 2021 at $755 and has fallen 57.7% since, to $319 in 2025.

$3,316in general payments, 2019–2025

Across 134 payments — averaging $24.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$1K
  • Organogenesis Inc.$497
  • Integra Lifesciences Corporation$285
  • Stryker$260
  • Johnson & Johnson$227
  • Medical Device Business Services, Inc.$118
  • plus $849 from 19 others

What the payments were for

  • Food & beverage$3,316100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,316 in reported general payments places this provider in the 85th percentile of 45 primary podiatric medicine providers in New Jersey.

See all primary podiatric medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$176,065
Medicare patients
423
Services billed
2,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.28$56,836
CiclopiroxCiclopirox Olamine168$2,826
Ammonium Lactate58$1,118
Doxycycline Monohydrate24$436
Ketoconazole16$394
Methylprednisolone44$323
Gabapentin38$291
Betamethasone Dipropionate14$239
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$185
Cephalexin13$98
Prednisone13$66
Tramadol Hcl11$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$1,080$56,83628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 45 primary podiatric medicine providers in New Jersey.

Other primary podiatric medicine in Mount Laurel

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →